Two young doctors from the Portuguese Institute of Oncology of Lisbon reviewed the clinical files of more than 2,000 patients with Differentiated Thyroid Cancer and evaluated the risk of developing other primary cancer elsewhere. They concluded that total administered activities of Iodine-131 above 200mCi could increase the risk. But the administration of low activities was not associated with the risk of having other cancers. The Differentiated Thyroid Cancer is the most common cancer in endocrinology and it is believed its incidence will increase in the next years.
